Related Experiment Video
Updated: Sep 17, 2025
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
Published on: November 24, 2014
State-of-the-art in oncolytic virotherapy using adenoviruses other than the commonly applied adenovirus type 5
Katrin Schröer1, Lotta Fiege1, Alina Wolf1
1Virology and Microbiology, Center for Education Biomedical Research (ZBAF), Department Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.
Abstract:
In most clinical trials, oncolytic viruses (OAds) based on human adenovirus type 5 (HAdV-C5) were explored, and only rarely a complete switch to another adenovirus type was evaluated. This review highlights the broader diversity of human adenoviruses and discusses advances in engineering non-HAdV-C5 OAds. We will discuss ongoing research to refine adenoviral constructs derived from alternative adenovirus species, including chimeric viruses, to optimize viral delivery and enhance antitumor immune responses. We summarize translational and clinical studies using these alternative OAds, emphasizing their therapeutic promise despite remaining challenges. Unlocking the full potential of diverse OAds could significantly expand cancer treatment options.
Insights
This review explores alternative adenovirus types beyond HAdV-C5 for oncolytic virus (OAd) cancer therapies. Engineering diverse OAds shows promise for improved viral delivery and enhanced antitumor immunity.
Area of Science:
- Oncolytic virotherapy
- Adenovirus engineering
- Cancer immunology
Background:
- Most oncolytic adenoviruses (OAds) utilize human adenovirus type 5 (HAdV-C5).
- Limited exploration of alternative adenovirus serotypes for OAd development.
- Need for diverse viral platforms to overcome HAdV-C5 limitations.
Purpose of the Study:
- Review advances in engineering non-HAdV-C5 OAds.
- Highlight the potential of diverse adenovirus species for cancer therapy.
- Discuss strategies to optimize viral delivery and antitumor immune responses.
Main Methods:
- Literature review of translational and clinical studies.
- Analysis of engineered adenoviral constructs from alternative species.
- Examination of chimeric adenovirus strategies.
Main Results:
- Ongoing research focuses on refining adenoviral constructs from alternative species.
- Chimeric viruses are being developed to optimize delivery and immune response.
- Alternative OAds demonstrate therapeutic promise in preclinical and clinical settings.
Conclusions:
- Diversifying adenovirus types beyond HAdV-C5 can expand cancer treatment options.
- Engineering non-HAdV-C5 OAds offers potential for enhanced efficacy.
- Further research is needed to overcome challenges and fully realize the potential of diverse OAds.
